Myriad (A): Breast Cancer Testing in Britain

Kellogg School of Management Cases

ISSN: 2474-6568

Publication date: 20 January 2017


Describes Myriad Genetics and its struggle to secure exclusive testing services for the BRCA gene. After Myriad obtained licensing rights and dissolved its U.S. competition, it turned its focus to Europe, specifically the United Kingdom. The U.K. National Health Service had made genetic testing available to the public and Myriad had to decide which course of action would be most effective in stopping British BRCA genetic testing and expanding Myriad's own service to this new market.



Diermeier, D. and Parthasarathy, S. (2017), "Myriad (A): Breast Cancer Testing in Britain", Kellogg School of Management Cases.

Download as .RIS



Kellogg School of Management

Copyright © 2004, The Kellogg School of Management at Northwestern University

Please note you might not have access to this content

You may be able to access this content by login via Shibboleth, Open Athens or with your Emerald account.
If you would like to contact us about accessing this content, click the button and fill out the form.